Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Halozyme Therapeutics (HALO) Tops Q3 EPS by 5c; Offers FY23 Guidance

HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

November 6, 2023 4:01 PM EST

Royalty Revenue Increased 15% YOY to Record $114.4 million

Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR

GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.751

Maintained Revenue Guidance and Raised 2023 EBITDA Guidance to $430-$445 million and Non-GAAP EPS Guidance to $2.70-$2.80    

SAN DIEGO, Nov. 6,... More